Antiviral assessments of honeybee (Apis mellifera L.) venom
Sang Mi Han1, Se Gun Kim1, Hyo Young Kim1, Hong Min Choi1, Hyo Jung Moon1, Soon Ok Woo1, Sok Cheon Pak2
1 Department of Agricultural Biology, National Institute of Agricultural Sciences, Wanju, Korea
2 School of Biomedical Sciences, Charles Sturt University, Bathurst, Australia
|Date of Submission||26-Jul-2019|
|Date of Decision||30-Sep-2019|
|Date of Acceptance||17-Feb-2020|
|Date of Web Publication||15-Jun-2020|
Sang Mi Han
Department of Agricultural Biology, National Institute of Agricultural Sciences, Wanju 55365
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: The poultry industry has long been challenged by avian influenza which causes significant economic loss due to decreased egg production and quality. In addition, the notable ability of influenza viruses to develop resistance to conventional antibiotics is one of the biggest tasks that the industry currently faces. Attempts have been made to treat this bird flu with multiple approaches, but effective natural solutions remain elusive. Bee venom (BV) is used for the treatment of various human diseases due to its known anti-inflammatory and antibacterial properties. Recent studies suggest that antimicrobial peptides discovered in BV may be utilized as tools for the design of structurally novel antiviral agents effective against influenza viruses. Materials and Methods: In the present study, we purified BV containing 63.9% ± 5.4% melittin, 10.9% ± 1.6% phospholipase A2, and 2.3% ± 0.3% apamin. BV was evaluated in vitro for its ability to inhibit the binding of H9N2 to the chicken red blood cells. Results: We found that anti-influenza activity of BV is equivalent to that of positive control. However, we observed the neutralization of H9N2 by BV as compared to the virus only group without BV. The hypothesized anti-influenza property of BV was further examined in chicken influenza infection model. The administration of BV through intranasal route resulted in no significant antiviral effect in chickens. Conclusion: This study does not support our hypothesis that BV can reduce the viral activity in chickens.
Keywords: Anti-viral, Apis mellifera , avian influenza, bee venom, H9N2
|How to cite this article:|
Han SM, Kim SG, Kim HY, Choi HM, Moon HJ, Woo SO, Pak SC. Antiviral assessments of honeybee (Apis mellifera L.) venom. Phcog Mag 2020;16:382-5
|How to cite this URL:|
Han SM, Kim SG, Kim HY, Choi HM, Moon HJ, Woo SO, Pak SC. Antiviral assessments of honeybee (Apis mellifera L.) venom. Phcog Mag [serial online] 2020 [cited 2021 Jul 25];16:382-5. Available from: http://www.phcog.com/text.asp?2020/16/69/382/286743
- We have purified bee venom (BV) from the honeybee and confirmed melittin as the main bioactive component by the ultra-performance liquid chromatography. BV was evaluated for its ability to inhibit the binding of H9N2 to chicken red blood cells (cRBCs). We have observed the neutralization of H9N2 by BV, implying that BV might possess a molecule to modulate the specific binding affinity of hemagglutination of H9N2 on the receptor of cRBCs.
Abbreviations used: AIV: Avian influenza virus; SPF: Specific pathogen-free; EID50: 50% egg infective dose; BV: Bee venom.
| Introduction|| |
Bird flu caused by avian influenza virus (AIV) keeps to appear mainly due to antigenic drift and antigenic shift characterized by multiple mutations, proving it notoriously variable., Inevitably, large-scale occurrences of influenza infections by the new virus are not uncommon. The various types of avian species, as well as several kinds of mammalian hosts, are involved in the ecology and epidemiology of influenza viruses. Due to the increased viral mutation rate, some existing vaccines are less likely to reduce the spread of influenza. Furthermore, it takes years for the existing technologies to create a new vaccine for a newly mutated virus. To make things more difficult, newly mutated viruses are decreasing the ability of the vaccine-induced antibody. Realistically, there is no immediate vaccine to deal with newly emerging virus outbreaks., To address these issues, there is a pressing need for the discovery of an alternative antiviral agent to control the spread of virus.
The therapeutic value of bee venom (BV) from honeybee (Apis mellifera L. ) to improve the quality of life of patients is acknowledged for more than 100 years. Modern approaches of venomics have allowed the discovery of venom constituents which were proven to be of pharmacological significance and have opened the way to optimization of therapeutic strategies through the use of active components such as melittin, apamin, and phospholipases. In particular, melittin, as a major peptide component of BV, is known to possess the multiple biological functions against cancer,,, liver fibrosis,, and atherosclerosis.,, For example, melittin prevented the development of the late stage and early stage prostate for the inhibition of cancer cells through apoptosis. This anticancer effect of BV was exerted the multiple effects on cellular functions of cancerous cells such as proliferation, apoptosis, metastasis, angiogenesis as well as cell cycle, and the anticancer processes involve diverse signal molecules and regulatory pathways. In addition, acute liver injury induced by lipopolysaccharide was attenudated by melittin treatment through the prevention of nuclear factor kappa Bactivation. Furthermore, melittin inhibited tumor necrosis factor-α-induced matrix metalloproteinase-9 protein expression which is involved in the pathogenesis of atherosclerosis in human aortic smooth muscle cells. However, the antiviral effect of BV has not been studied in AIV. Therefore, it was hypothesized that BV can reduce viral activity in chickens. To examine this hypothesis, the current study performed the anti-influenza activity of BV against chickens infected with AIV.
| Materials and Methods|| |
Preparation of purified bee venom
The colonies of natural honey bees used in this study were maintained at the National Academy of Agricultural Science, Wanju, Korea. BV was collected using a BV collecting device (Chungjin, Korea) in a sterile manner under strict laboratory conditions. In brief, the BV collector was placed in the hive, and the bees were given enough electric shock to cause them to sting a glass plate from which dried BV was later scraped off. The collected BV was diluted in cold sterile water and then centrifuged at 10,000 g for 5 min at 4°C to discard the residues from the supernatant. BV was lyophilized by a freeze dryer and refrigerated at 4°C for later use. The amount of 3.2 mg BV was suspended in sterile distilled water and centrifuged at 3000 rpm for 10 min at 4°C. The supernatant was filtered through a 0.2 μm syringe filter (Corning, Germany) to remove any remaining particular material before use. The ultra-performance liquid chromatography analysis of the purified BV revealed three peaks matching those of the commercial standards, apamin, phospholipase A2, and melittin, with retention times of approximately 1.8 min, 4.3 min, and 8.8 min, respectively. The purified BV contained 63.9% ± 5.4% melittin, 10.9% ± 1.6% phospholipase A2, and 2.3% ± 0.3% apamin.
AIV A/chicken/Korea/MS96/96 (H9N2) was propagated in 9-day-old specific pathogen-free (SPF) embryonated chicken eggs for 72 h in an incubator at 38°C. The eggs were then chilled at 4°C to kill the embryo and to reduce the contamination of the allantoic fluid with blood during harvesting. Allantoic fluids of the inoculated eggs were collected and centrifuged at 3000 rpm for 5 min and supernatants were diluted for use.
In vitro experiment
Prepared diluted working seed of AIV (10−1 ~ 10−8) and BV (32, 16, 8, 4, 2, and 1 ppm) solution mixture was inoculated into 270 SPF embryonated chicken eggs at the rate of 0.1 ml per egg through intraallantoic way. All eggs were sealed with wax. Inoculated eggs were incubated for 72 h in an incubator at 38°C. Eggs were candled daily, and early death embryos in the first 24 h were removed. The allantoic fluid sample from each egg was withdrawn into the small measuring cylinder until the total volume of 1 ml was obtained in the harvesting stage. Allantoic fluids were then tested for 50% egg infective dose (EID50). EID50 of the samples, determined by the dose of AIV that caused a cytopathic effect in 50% of the inoculated eggs, was calculated by the method of Reed and Muench mathematical technique. EID50 was then used to calculate the log-scale reduction in infective dose. Assay for EID50 was performed in three replicates. The results were also included to analyze both positive (virus with sodium dichloroisocyanurate) and negative (virus without BV) controls.
Three-week-old SPF chickens were purchased from Namduck Sanitek (Korea). Chickens were maintained the SPF laboratory conditions in a chicken isolator for 3 days beforein vivo experiment.
In vivo experiment
Forty chickens were divided into four groups [Table 1]. Chickens were challenged with 10 EID50/100 μl H9N2 viruses by the intranasal route. Before virus challenge, chickens were orally administered with three doses (10, 100, and 1000 ng/g) of BV daily for 1 week. For the following 2 weeks since the virus challenge, higher doses (20, 200, and 2000 ng/g) of BV were fed every other day. After the virus challenge, oral and cloacal swabs were collected every other day for the evaluation of viral shedding using the real-time polymerase chain reaction (RT-PCR). Swabs were allowed to stand in tubes containing 1.0 ml sterile phosphate-buffered saline, pH 7.2 frozen at −70°C for analysis. Following experimental infection, chickens were also checked daily for any clinical signs and mortality.
|Table 1: In vivo experimental design of H9N2 with specific pathogen-free chickens|
Click here to view
Real-time polymerase chain reaction assay
Culture RNA was extracted with the viral gene-spin RNA/DNA extraction kit (Intron, Korea) with a modified protocol for sample recommended by the manufacturer. The forward primer sequence was 5'-AGATGAGTCTTCTAACCGAGGTCG-3'; the reverse primer was 5'-TGCAAAAACATCTTCAAGTCTCTG-3'; and the probe sequence was 5'-TCAGGCCCCCTCAAAGCCGA-3'. Probe was labeled at the 5' end with the 6-carboxyfluorescein (FAM) reporter dye and at the 3' end with the 6-carboxytetramethylrhodamine (TAMRA) quencher dye. PCR mixtures were prepared in a total volume of 50 μl with the QuantiTect Probe RT-PCR kit (Qiagen, Valencia, CA, USA) under the following conditions: 25.5 μl of kit-supplied enzyme mixture, 0.4 μM each primer, 0.1 μM probe, 5 μl of RNA. The RT step conditions for all primers were 30 min at 50°C and 15 min at 95°C. A three-step PCR cycling protocol was used for the matrix gene primer as follows: 40 cycles of 94°C for 10 s, 55°C for 30 s, and 72°C for 10 s. Fluorescence data were acquired at the end of each annealing step. Real-time RT-PCR was performed with Applied Biosystems 7500 Fast real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA).
Data are presented as mean ± standard deviation of at least three independent experiments. All analyses were conducted using the R is a free software environment for statistical computing. For evaluating statistical significance, one-way analysis of variance test along with Fisher's least significant difference was used. P ≤0.01 is considered statistically significant.
| Results|| |
50% egg infective dose test
Means of EID50 test in the study groups are shown in [Table 2]. BV was investigated for its effectiveness in the prevention of binding of viruses to the chicken red blood cells (cRBCs). BV binds to the hemagglutinin present in the viruses. As a result, viruses are neutralized; hence, preventing hemagglutinin-mediated binding of viruses with sialic acids present in the surface of cRBCs. No significant differences were seen for EID50 test between positive control and BV added groups. Only in negative control without BV, EID50 test result was significantly increased. Overall, EID50 test was evaluated in different doses of BV for prepared AIV, and there were not any significant differences between treatment groups, including positive control.
|Table 2: The anti-influenza virus activity of bee venom against A/chicken/Korea/MS96/96 (H9N2)|
Click here to view
In vivo assay of bee venom against H9N2
The real-time RT-PCR, also called quantitative PCR, analysis of oral and cloacal swabs of each chicken was used for the determination of virus load on these chickens. Higher numbers of viruses were detected in both oral and cloacal swab samples than negative control. Overall, we did not notice any reduction in the virus load from BV-treated chickens [Figure 1].
|Figure 1: In vivo study of prevention of H9N2 infection by bee venom in specific pathogen-free chickens. Number of virus count of oral swab (a) and cloacal swab (b)|
Click here to view
| Discussion|| |
The primary objective of the present study was to investigate the possibility of using BV as an anti-influenza agent for animals. According to previous studies, BV has been shown to exert anti-microbial effects against bovine mastitis, and fish pathogens. While BV decreased the elevated somatic cell count from mastitic quarters, BV also decreased lipopolysaccharide (LPS)-induced inflammatory responses in bovine mammary epithelial cells. In addition, BV inhibited the growth and survival of three bacterial strains.
Bird flu or avian influenza is a viral infection occurring worldwide with subsequent economic and health problems. Due to its high pathogenicity, an influenza pandemic is inevitable and potentially threating humans as well as livestock. Among many types of AIV, H9N2 is known as low pathogenic avian influenza. However, it causes an endemic outbreak in the poultry industry in many Asian countries. The poultry outbreaks of H9N2 are associated with significant economic losses because of low egg production, reduced feed conversion efficiencies, and highly lethal bacterial or viral coinfections. Unfortunately, H9N2 subtype AI virus during 2007 outbreak in Korea was reported to escape vaccine protection due to the excessive use of animal vaccination.
The influenza viruses, typically influenza A and B viruses, possess eight pieces of viral RNA. These viruses contain a host cell-derived envelope membrane carrying the hemagglutination glycoprotein. Hemagglutination as the surface antigen is responsible for most antigenic variations and contains binding site for sialic acid residues on the surface of target cells, mediating the binding of the virus to target cells and the subsequent entry of the viral genome. As such, one of the criteria for a new agent is the inhibition of viral intrusion into host cells through hemagglutination. In this study, we observed the neutralization of H9N2 by BV compared to the virus only group without BV. It is possible that BV possesses a molecule to interrupt the specific-binding affinity of hemagglutination of H9N2 on receptor of cRBCs. According to Pandey et al ., receptor specificities the hemagglutination of viruses can be different depending on different viral strains. It implies that antiviral efficacy of BV could be changed against different types of virus strains. Furthermore, BV was applied for the control of H9N2 virus infection in chickens, which resulted in no significant differences. Our preliminaryin vivo data of BV against H9N2 infection require further extensive study.
Authors are thankful to Rural Development Administration, Republic of Korea.
Financial support and sponsorship
This work was supported by a grant (code #PJ01316602) from the Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine 2007;25:5637-44.
Capua I, Alexander DJ. Avian influenza: Recent developments. Avian Pathol 2004;33:393-404.
Lee HJ, Lee YN, Youn HN, Lee DH, Kwak JH, Seong BL, et al
. Anti-influenza virus activity of green tea by-products in vitro
and efficacy against influenza virus infection in chickens. Poult Sci 2012;91:66-73.
Gao Q, Chou YY, Doǧanay S, Vafabakhsh R, Ha T, Palese P. The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging. J Virol 2012;86:7043-51.
Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007;7:267-78.
Jeong CH, Cheng WN, Bae H, Lee KW, Han SM, Petriello MC, et al
. Bee venom decreases LPS-induced inflammatory responses in bovine mammary epithelial cells. J Microbiol Biotechnol 2017;27:1827-36.
Piek T. Venoms of the Hymenoptera: Biochemical, Pharmacological and Behavioural Aspects. London: Academic Press; 1986.
Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, et al
. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol 2012;258:72-81.
Park JH, Jeong YJ, Park KK, Cho HJ, Chung IK, Min KS, et al
. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells 2010;29:209-15.
Park MH, Choi MS, Kwak DH, Oh KW, Yoon DY, Han SB, et al
. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB. Prostate 2011;71:801-12.
Jeong YJ, Cho HJ, Whang K, Lee IS, Park KK, Choe JY, et al
. Melittin has an inhibitory effect on TNF-α-induced migration of human aortic smooth muscle cells by blocking the MMP-9 expression. Food Chem Toxicol 2012;50:3996-4002.
Park JH, Kim KH, Lee WR, Han SM, Park KK. Protective effect of melittin on inflammation and apoptosis in acute liver failure. Apoptosis 2012;17:61-9.
Kim SJ, Park JH, Kim KH, Lee WR, Kim KS, Park KK. Melittin inhibits atherosclerosis in LPS/high-fat treated mice through atheroprotective actions. J Atheroscler Thromb 2011;18:1117-26.
Son DJ, Ha SJ, Song HS, Lim Y, Yun YP, Lee JW, et al
. Melittin inhibits vascular smooth muscle cell proliferation through induction of apoptosis via suppression of nuclear factor-kappaB and Akt activation and enhancement of apoptotic protein expression. J Pharmacol Exp Ther 2006;317:627-34.
Reed LJ, Muench H. A simple method of estimating fifty percent end points. Ame J Hygiene 1938;27:493-7.
Han SM, Lee KG, Yeo JH, Hwang SJ, Jang CH, Chenoweth PJ, et al
. Somatic cell count in milk of bee venom treated dairy cows with mastitis. J Api Prod Api Med Sci 2009;1:104-9.
Han SM, Lee KG, Park KK, Pak SC. Antimicrobial activity of honey bee venom against select infectious fish pathogens. N
Ame J Aquac 2013;75:445-8.
Thuy DM, Peacock TP, Bich VT, Fabrizio T, Hoang DN, Tho ND, et al
. Prevalence and diversity of H9N2 avian influenza in chickens of Northern Vietnam, 2014. Infect Genet Evol 2016;44:530-40.
Pandey RP, Kim DH, Woo J, Song J, Jang SH, Kim JB, et al
. Broad-spectrum neutralization of avian influenza viruses by sialylated human milk oligosaccharides: In vivo
assessment of 3'-sialyllactose against H9N2 in chickens. Sci Rep 2018;8:2563.
Jeong HJ, Ryu YB, Park SJ, Kim JH, Kwon HJ, Kim JH, et al
. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea
roots and their in vitro
anti-influenza viral activities. Bioorg Med Chem 2009;17:6816-23.
[Table 1], [Table 2]